BioCryst to Present at JMP Securities Hematology & Oncology Summit

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present virtually at the JMP Securities Hematology & Oncology Summit on December 7, 2022, at 11:40 a.m. ET. The presentation will be accessible via a live audio webcast on their website. The company specializes in developing oral, small-molecule medications for rare diseases, with its product ORLADEYO^® (berotralstat) already approved in the U.S. BioCryst also has ongoing clinical programs for oral factor D inhibitors BCX9930 and BCX10013.

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET.

Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including oral factor D inhibitors BCX9930 and BCX10013, which are in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com 

FAQ

When will BioCryst Pharmaceuticals present at the JMP Securities Hematology & Oncology Summit?

BioCryst Pharmaceuticals will present on December 7, 2022, at 11:40 a.m. ET.

How can I access the BioCryst Pharmaceuticals presentation?

The presentation can be accessed via a live audio webcast on BioCryst's website.

What is ORLADEYO and its approval status?

ORLADEYO^® (berotralstat) is an oral medication approved in the U.S. and other global markets.

What other products are being developed by BioCryst Pharmaceuticals?

BioCryst is developing oral factor D inhibitors BCX9930 and BCX10013, which are currently in clinical development.